{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T04:21:09Z","timestamp":1744258869339,"version":"3.40.4"},"reference-count":84,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"2","license":[{"start":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T00:00:00Z","timestamp":1629590400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Alerg Mex"],"abstract":"<jats:p>Chronic granulomatous disease (CGD) is an inborn error of immunity that affects the functionality of phagocytosis; specifically, there\u2019s lack of production of oxygen-free radicals by NADPH oxidase. CGD manifests as severe and recurring bacterial and fungal infections, as well as local and systemic hyperinflammation. In countries where tuberculosis is endemic and the BCG vaccine is mandatory at birth, patients with CGD may present local or systemic reactions to this vaccine as first manifestation; besides, recurrent infections by M. tuberculosis may be present throughout their life. The susceptibility of these patients to mycobacteria is due to the excessive production of pro-inflammatory cytokines and the formation of granulomas that are inefficient in containing mycobacteria. In developed countries, patients with CGD do not present this type of infectious manifestations, except for migrants who come from developing countries. In this review, we present the characteristics of infections by BCG, M. tuberculosis, and other types of mycobacteria. Interestingly, there are no guidelines regarding anti-tuberculosis treatments in patients with CGD, so we propose the realization of a consensus by experts in order to establish guidelines for the treatment of mycobacterial disease in CGD.<\/jats:p>","DOI":"10.29262\/ram.v658i2.859","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:50:29Z","timestamp":1631839829000},"page":"117-127","source":"Crossref","is-referenced-by-count":1,"title":["Enfermedad por micobacterias en pacientes con enfermedad granulomatosa cr\u00f3nica","Mycobacterial disease in patients with chronic granulomatous disease"],"prefix":"10.29262","volume":"68","author":[{"given":"Beatriz","family":"Garc\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ximena","family":"Le\u00f3n-Lara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizbeth","family":"Blancas-Galicia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11808","published-online":{"date-parts":[[2021,8,22]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Bousfiha A, Jeddane L, Picard C, Al-Herz W, Ailal F, Chatila T, et al. Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification. J Clin Immunol. 2020;40(1):66-81. DOI: 10.1007\/s10875-020-00758-x","DOI":"10.1007\/s10875-020-00758-x"},{"key":"ref1","unstructured":"Coria-Ramirez E, Espinosa-Padilla S, Espinosa-Rosales F, Vargas-Camano ME, Blancas-Galicia L. An overview of primary immunodeficiency in Mexico. Rev Alerg Mex. 2010;57(5):159-163."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Abraham RS Aubert G. Flow cytometry, a versatile tool for diagnosis and monitoring of primary immunodeficiencies. Clin Vaccine Immunol. 2016;23(4):254-271. DOI: 10.1128\/CVI.00001-16","DOI":"10.1128\/CVI.00001-16"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Amaya-Uribe L, Rojas M, Azizi G, Anaya JM, Gershwin ME. Primary immunodeficiency and autoimmunity: a comprehensive review. J Autoimmun. 2019;99:52-72. DOI: 10.1016\/j.jaut.2019.01.011","DOI":"10.1016\/j.jaut.2019.01.011"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Hern\u00e1ndez-Mart\u00ednez C, Espinosa-Rosales F, Espinosa-Padilla SE, Hern\u00e1ndez-Mart\u00ednez AR, Blancas-Galicia L. Conceptos b\u00e1sicos de las inmunodeficiencias primarias. Rev Alerg Mex. 2016(2);63:180-189. Disponible en: https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/146\/307","DOI":"10.29262\/ram.v63i2.146"},{"key":"ref5","unstructured":"Espinosa-Padilla S, Guzm\u00e1n-Mart\u00ednez M, Venegas-Montoya E, Jim\u00e9nez-Polvo N, Medina-Torres A, Segura-M\u00e9ndez N, et al. Capacitaci\u00f3n en hospitales de M\u00e9xico para el diagn\u00f3stico de enfermedad granulomatos cr\u00f3nica por la t\u00e9cnica de 1-2-3 dihidrorrodamina. Alerg Asma Inmunol Pediatr. 2017;26(3):76-83. Disponible en: https:\/\/www.medigraphic.com\/pdfs\/alergia\/al-2017\/al173b.pdf"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Arnold DE, Heimall JR. A review of chronic granulomatous disease. Adv Ther. 2017;34(12):2543-2557. DOI: 10.1007\/s12325-017-0636-2","DOI":"10.1007\/s12325-017-0636-2"},{"key":"ref7","unstructured":"Medrano-E'Vers A, Morales-Hern\u00e1ndez, AE, Valencia-L\u00f3pez, R, Hern\u00e1ndez-Salcedo, DR. Enfermedad granulomatosa cr\u00f3nica. Med Intern Mex. 2017;33:3407-3414."},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Rawat A, Bhattad S, Singh S. Chronic Granulomatous Disease. Indian J Pediatr. 2016;83(4):345-353. DOI: 10.1007\/s12098-016-2040-3","DOI":"10.1007\/s12098-016-2040-3"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Rider NL, Jameson MB, Creech CB. Chronic granulomatous disease: epidemiology, pathophysiology, and genetic basis of disease. J Pediatric Infect Dis Soc. 2018;7(Suppl 1):S2-S5. DOI: 10.1093\/jpids\/piy008","DOI":"10.1093\/jpids\/piy008"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Roos D. Chronic granulomatous disease. Methods Mol Biol. 2019;1982:531-542. DOI: 10.1007\/978-1-4939-9424-3_32","DOI":"10.1007\/978-1-4939-9424-3_32"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore). 2000;79(3):170-200. DOI: 10.1097\/00005792-200005000-00004","DOI":"10.1097\/00005792-200005000-00004"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Wang S, Wang T, Xiang Q, Xiao M, Cao Y, Xu H, et al. Clinical and molecular features of chronic granulomatous disease in mainland China and a XL-CGD female infant patient after prenatal diagnosis. J Clin Immunol. 2019;39(8):762-775. DOI: 10.1007\/s10875-019-00680-x","DOI":"10.1007\/s10875-019-00680-x"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Yu H-H, Yang Y-H, Chiang B-L. Chronic granulomatous disease: a comprehensive review. 2020. DOI: 10.1007\/s12016-020-08800-x","DOI":"10.1007\/s12016-020-08800-x"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Thomas DC, Clare S, Sowerby JM, Pardo M, Juss JK, Goulding DA, et al. Eros is a novel transmembrane protein that controls the phagocyte respiratory burst and is essential for innate immunity. J Exp Med. 2017;214(4):1111-1128. DOI: 10.1084\/jem.20161382","DOI":"10.1084\/jem.20161382"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Bianchi M, Hakkim A, Brinkmann V, Siler U, Seger RA, Zychlinsky A, et al. Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood. 2009;114(13):2619-2622. DOI: 10.1182\/blood-2009-05-221606","DOI":"10.1182\/blood-2009-05-221606"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Lopez-Hern\u00e1ndez I, Su\u00e1rez-Guti\u00e9rrez M, Santos-Ch\u00e1vez EE, Espinosa S, Blancas-Galicia L. Chronic granulomatous disease. Update and review. Rev Alerg Mex. 2019;66(2):232-245.","DOI":"10.29262\/ram.v66i2.577"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Prince BT, Thielen BK, Williams KW, Kellner ES, Arnold DE, Cosme-Blanco W, et al. Geographic variability and pathogen-specific considerations in the diagnosis and management of chronic granulomatous disease. Pediatric Health Med Ther. 2020;22(11):257-268. DOI: 10.2147\/PHMT.S254253","DOI":"10.2147\/PHMT.S254253"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Blancas-Galicia L, Santos-Ch\u00e1vez E, Deswarte C, Mignac Q, Medina-Vera I, Le\u00f3n-Lara X, et al. Genetic, immunological, and clinical features of the first Mexican cohort of patients with chronic granulomatous disease. J Clin Immunol. 2020;40(3):475-493. DOI: 10.1007\/s10875-020-00750-5","DOI":"10.1007\/s10875-020-00750-5"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Lacerda-Pontes R, Gomes LN, de Albuquerque RS, Soeiro-Pereira PV, Condino-Neto A. The extended understanding of chronic granulomatous disease. Curr Opin Pediatr. 2019;31(6):869-873. DOI: 10.1097\/MOP.0000000000000830","DOI":"10.1097\/MOP.0000000000000830"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Bustamante J, Aksu G, Vogt G, de Beaucoudrey L, Genel F, Chapgier A, et al. BCG-osis and tuberculosis in a child with chronic granulomatous disease. J Allergy Clin Immunol. 2007;120(1):32-38. DOI: 10.1016\/j.jaci.2007.04.034","DOI":"10.1016\/j.jaci.2007.04.034"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Mortaz E, Azempour E, Mansouri D, Tabarsi P, Ghazi M, Koenderman L, et al. Common infections and target organs associated with chronic granulomatous disease in Iran. Int Arch Allergy Immunol. 2019;179(1):62-73. DOI: 10.1159\/000496181","DOI":"10.1159\/000496181"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Marciano BE, Spalding C, Fitzgerald A, Mann D, Brown T, Osgood S, et al. Common severe infections in chronic granulomatous disease. Clin Infect Dis. 2015;60(8):1176-1183. DOI: 10.1093\/cid\/ciu1154","DOI":"10.1093\/cid\/ciu1154"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Sasindran SJ, Torrelles JB. Mycobacterium Tuberculosis infection and inflammation: what is beneficial for the host and for the bacterium? Front Microbiol. 2011;2(2). DOI: 10.3389\/fmicb.2011.00002","DOI":"10.3389\/fmicb.2011.00002"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Olive AJ, Clare MS, Kiritsy MC, Sassetti CM. The phagocyte oxidase controls tolerance to Mycobacterium tuberculosis infection. J Immunol. 2018;201(6):1705-1716. DOI: 10.4049\/jimmunol.1800202","DOI":"10.4049\/jimmunol.1800202"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Deffert C, Schappi MG, Pache JC, Cachat J, Vesin D, Bisig R, et al. Bacillus calmette-guerin infection in NADPH oxidase deficiency: defective mycobacterial sequestration and granuloma formation. PLoS Pathog. 2014;10(9):e1004325. DOI: 10.1371\/journal.ppat.1004325","DOI":"10.1371\/journal.ppat.1004325"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Yang C-S, Shin D-M, Kim K-H, Lee Z-W, Lee C-H, Park S-G, et al. NADPH oxidase 2 interaction with TLR2 is required for efficient innate immune responses to mycobacteria via cathelicidin expression. J Immunol. 2009;182(6):3696-3705. DOI: 10.4049\/jimmunol.0802217","DOI":"10.4049\/jimmunol.0802217"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Liu W, Peng Y, Yin Y, Zhou Z, Zhou W, Dai Y. The involvement of NADPH oxidase-mediated ROS in cytokine secretion from macrophages induced by Mycobacterium tuberculosis ESAT-6. Inflammation. 2014;37(3):880-892. DOI: 10.1007\/s10753-013-9808-7","DOI":"10.1007\/s10753-013-9808-7"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Voskuil MI, Bartek IL, Visconti K, Schoolnik GK. The response of mycobacterium tuberculosis to reactive oxygen and nitrogen species. Front Microbiol. 2011;2(105):105. DOI: 10.3389\/fmicb.2011.00105","DOI":"10.3389\/fmicb.2011.00105"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Ng VH, Cox JS, Sousa AO, MacMicking JD, McKinney JD. Role of KatG catalase-peroxidase in mycobacterial pathogenesis: countering the phagocyte oxidative burst. Mol Microbiol. 2004;52(5):1291-1302. DOI: 10.1111\/j.1365-2958.2004.04078.x","DOI":"10.1111\/j.1365-2958.2004.04078.x"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Cachat J, Deffert C, Hugues S, Krause K-H. Phagocyte NADPH oxidase and specific immunity. Clin Sci (Lond). 2015;128(10):635-648. DOI: 10.1042\/CS20140635","DOI":"10.1042\/CS20140635"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Casanova JL AL. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol. 2002;20:581-620. DOI: 10.1146\/annurev.immunol.20.081501.125851","DOI":"10.1146\/annurev.immunol.20.081501.125851"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Lee W-I, Huang J-L, Yeh K-W, Jaing T-H, Lin T-Z, Huang Y-C, et al. Immune defects in active mycobacterial diseases in patients with primary immunodeficiency diseases (PIDs). J Formos Med Assoc. 2011;110(12):750-758. DOI: 10.1016\/j.jfma.2011.11.004","DOI":"10.1016\/j.jfma.2011.11.004"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Li T, Zhou X, Ling Y, Jiang N, Ai J, Wu J, et al. Genetic and clinical profiles of disseminated bacillus calmette-guerin disease and chronic granulomatous disease in China. Front Immunol. 2019;10:73. DOI: 10.3389\/fimmu.2019.00073","DOI":"10.3389\/fimmu.2019.00073"},{"key":"ref34","unstructured":"Berlanga L. Introduction of BCG vaccination in Mexico. Arch Pediatr Urug. 1950;21(7):563-564."},{"key":"ref35","unstructured":"Santos J. El Programa Nacional de Vacunaci\u00f3n: orgullo de M\u00e9xico. Rev Fac Med. 2002;45(3):142-153. Disponible en: https:\/\/www.medigraphic.com\/pdfs\/facmed\/un-2002\/un023g.pdf"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Med. 2011;8(3):e1001012. DOI: 10.1371\/journal.pmed.1001012","DOI":"10.1371\/journal.pmed.1001012"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"van den Berg JM, van Koppen E, Ahlin A, Belohradsky BH, Bernatowska E, Corbeel L, et al. Chronic granulomatous disease: the European experience. PLoS One. 2009;4(4):e5234. DOI: 10.1371\/journal.pone.0005234","DOI":"10.1371\/journal.pone.0005234"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Zhou Q, Hui X, Ying W, Hou J, Wang W, Liu D, et al. A cohort of 169 chronic granulomatous disease patients exposed to BCG vaccination: a retrospective study from a single center in Shanghai, China (2004-2017). J Clin Immunol. 2018;38(3):260-272. DOI: 10.1007\/s10875-018-0486-y","DOI":"10.1007\/s10875-018-0486-y"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"de Oliveira-Junior EB, Zurro NB, Prando C, Cabral-Marques O, Pereira PV, Schimke LF, et al. Clinical and genotypic spectrum of chronic granulomatous disease in 71 Latin American patients: first report from the LASID Registry. Pediatr Blood Cancer. 2015;62(12):2101-2107. DOI: 10.1002\/pbc.25674","DOI":"10.1002\/pbc.25674"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Conti F, Lugo-Reyes SO, Blancas-Galicia L, He J, Aksu G, Borges-de Oliveira E, et al. Mycobacterial disease in patients with chronic granulomatous disease: a retrospective analysis of 71 cases. J Allergy Clin Immunol. 2016;138(1):241-248. DOI: 10.1016\/j.jaci.2015.11.041","DOI":"10.1016\/j.jaci.2015.11.041"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Pasic S, Minic A, Minic P, Veljkovic D, Lilic D, Slavkovic B, et al. Long-term follow-up and prognosis of chronic granulomatous disease in Yugoslavia: is there a role for early bone marrow transplantation? J Clin Immunol. 2003;23(1):55-61. DOI: 10.1023\/a:1021952315651","DOI":"10.1023\/A:1021952315651"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Movahedi M, Aghamohammadi A, Rezaei N, Shahnavaz N, Jandaghi AB, Farhoudi A, et al. Chronic granulomatous disease: a clinical survey of 41 patients from the Iranian primary immunodeficiency registry. Int Arch Allergy Immunol. 2004;134(3):253-259. DOI: 10.1159\/000078774","DOI":"10.1159\/000078774"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Kutukculer N, Aykut A, Karaca NE, Durmaz A, Aksu G, Genel F, et al. Chronic granulamatous disease: two decades of experience from a paediatric immunology unit in a country with high rate of consangineous marriages. Scand J Immunol. 2019;89(2):e12737. DOI: 10.1111\/sji.12737","DOI":"10.1111\/sji.12737"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Koker MY, Camcioglu Y, van Leeuwen K, Kilic SS, Barlan I, Yilmaz M, et al. Clinical, functional, and genetic characterization of chronic granulomatous disease in 89 Turkish patients. J Allergy Clin Immunol. 2013;132(5):1156-1163. DOI: 10.1016\/j.jaci.2013.05.039","DOI":"10.1016\/j.jaci.2013.05.039"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Gao L-W, Yin Q-Q, Tong Y-J, Gui J-G, Liu X-Y, Feng X-L, et al. Clinical and genetic characteristics of Chinese pediatric patients with chronic granulomatous disease. Pediatr Allergy Immunol. 2019;30(3):378-386. DOI: 10.1111\/pai.13033","DOI":"10.1111\/pai.13033"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Xu H, Tian W, Li SJ, Zhang LY, Liu W, Zhao Y, et al. Clinical and molecular features of 38 children with chronic granulomatous disease in mainland China. J Clin Immunol. 2014;34(6):633-641. DOI: 10.1007\/s10875-014-0061-0","DOI":"10.1007\/s10875-014-0061-0"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"de Jong BC, Onipede A, Pym AS, Gagneux S, Aga RS, DeRiemer K, et al. Does resistance to pyrazinamide accurately indicate the presence of Mycobacterium bovis? J Clin Microbiol. 2005;43(7):3530-3532. DOI: 10.1128\/JCM.43.7.3530-3532.2005","DOI":"10.1128\/JCM.43.7.3530-3532.2005"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Wu J, Wang W-F, Zhang Y-D, Chen T-X. Clinical features and genetic analysis of 48 patients with chronic granulomatous disease in a single center study from Shanghai, China (2005-2015): new studies and a literature review. J Immunol Res. 2017;2017:8745254. DOI: 10.1155\/2017\/8745254","DOI":"10.1155\/2017\/8745254"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Ying W, Sun J, Liu D, Hui X, Yu Y, Wang J, et al. Clinical characteristics and immunogenetics of BCGosis\/BCGitis in Chinese children: a 6 year follow-up study. PLoS One. 2014;9(4):e94485. DOI: 10.1371\/journal.pone.0094485","DOI":"10.1371\/journal.pone.0094485"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Winkelstein JA, Marino MC, Johnston RB, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore). 2000;79(3):155-169. DOI: 10.1097\/00005792-200005000-00003","DOI":"10.1097\/00005792-200005000-00003"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Hargreaves S, L\u00f6nnroth K, Nellums LB, Olaru ID, Nathavitharana RR, Norredam M, et al. Multidrug-resistant tuberculosis and migration to Europe. Clin Microbiol Infect. 2017;23(3):141-146. DOI: 10.1016\/j.cmi.2016.09.009","DOI":"10.1016\/j.cmi.2016.09.009"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Lee PPW, Chan K-W, Jiang L, Chen T, Li C, Lee TL, et al. Susceptibility to mycobacterial infections in children with X-linked chronic granulomatous disease: a review of 17 patients living in a region endemic for tuberculosis. Pediatr Infect Dis J. 2008;27(3):224-230. DOI: 10.1097\/INF.0b013e31815b494c","DOI":"10.1097\/INF.0b013e31815b494c"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Aygun D, Koker MY, Nepesov S, Koker N, van Leeuwen K, de Boer M, et al. Genetic characteristics, infectious, and noninfectious manifestations of 32 patients with chronic granulomatous disease. Int Arch Allergy Immunol. 2020;181(7):540-550. DOI: 10.1159\/000507366","DOI":"10.1159\/000507366"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Kulkarni M, Desai M, Gupta M, Dalvi A, Taur P, Terrance A, et al. Clinical, immunological, and molecular findings of patients with p47(phox) defect chronic granulomatous disease (CGD) in Indian families. J Clin Immunol. 2016;36(8):774-784. DOI: 10.1007\/s10875-016-0333-y","DOI":"10.1007\/s10875-016-0333-y"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Fattahi F, Badalzadeh M, Sedighipour L, Movahedi M, Fazlollahi MR, Mansouri SD, et al. Inheritance pattern and clinical aspects of 93 Iranian patients with chronic granulomatous disease. J Clin Immunol. 2011;31(5):792-801. DOI: 10.1007\/s10875-011-9567-x","DOI":"10.1007\/s10875-011-9567-x"},{"issue":"12","key":"ref56","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jfma.2011.11.004","article-title":"Immune defects in active mycobacterial diseases in patients with primary immunodeficiency diseases (PIDs)","volume":"110","author":"Lee","year":"2011","unstructured":"Lee WI, Huang JL, Yeh KW, Jaing TH, Lin TY, Huang YC, et al. Immune defects in active mycobacterial diseases in patients with primary immunodeficiency diseases (PIDs). J Formos Med Assoc. 2011;110(12):750-8.","journal-title":"J Formos Med Assoc"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Allen DM, Chng HH. Disseminated Mycobacterium flavescens in a probable case of chronic granulomatous disease. J Infect. 1993;26(1):83-86. DOI: 10.1016\/0163-4453(93)97000-n","DOI":"10.1016\/0163-4453(93)97000-N"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Ohga S, Ikeuchi K, Kadoya R, Okada K, Miyazaki C, Suita S, et al. Intrapulmonary Mycobacterium avium infection as the first manifestation of chronic granulomatous disease. J Infect. 1997;34(2):147-150. DOI: 10.1016\/s0163-4453(97)92509-3","DOI":"10.1016\/S0163-4453(97)92509-3"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Weening RS, de Boer M, Kuijpers TW, Neefjes VM, Hack WW, Roos D. Point mutations in the promoter region of the CYBB gene leading to mild chronic granulomatous disease. Clin Exp Immunol. 2000;122(3):410-417. DOI: 10.1046\/j.1365-2249.2000.01405.x","DOI":"10.1046\/j.1365-2249.2000.01405.x"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Chusid MJ, Parrillo JE, Fauci AS. Chronic granulomatous disease. Diagnosis in a 27-year-old man with Mycobacterium fortuitum. JAMA. 1975;233(12):1295-1296. DOI: 10.1001\/jama.233.12.1295","DOI":"10.1001\/jama.233.12.1295"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"El-Mokhtar MA, Salama EH, Fahmy EM, Mohamed ME. Clinical aspects of chronic granulomatous disease in upper Egypt. Immunol Invest. 2020;22(2-3):1-13. DOI: 10.1080\/08820139.2020.1713144","DOI":"10.1080\/08820139.2020.1713144"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Dunogue B, Pilmis B, Mahlaoui N, Elie C, Coignard-Biehler H, Amazzough K, et al. Chronic granulomatous disease in patients reaching adulthood: a nationwide study in France. Clin Infect Dis. 2017;64(6):767-775. DOI: 10.1093\/cid\/ciw837","DOI":"10.1093\/cid\/ciw837"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Rawat A, Vignesh P, Sharma A, Shandilya JK, Sharma M, Suri D, et al. Infection profile in chronic granulomatous disease: a 23-year experience from a tertiary care center in North India. J Clin Immunol. 2017;37(3):319-328. DOI: 10.1007\/s10875-017-0382-x","DOI":"10.1007\/s10875-017-0382-x"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Meshaal S, Hawary RE, Elaziz DA, Alkady R, Galal N, Boutros J, et al. Chronic granulomatous disease: review of a cohort of Egyptian patients. Allergol Immunopathol (Madr). 2015;43(3):279-285. DOI: 10.1016\/j.aller.2014.11.003","DOI":"10.1016\/j.aller.2014.11.003"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Al-Zadjali S, Al-Tamemi S, Elnour I, AlKindi S, Lapoumeroulie C, Al-Maamari S, et al. Clinical and molecular findings of chronic granulomatous disease in Oman: family studies. Clin Genet. 2015;87(2):185-189. DOI: 10.1111\/cge.12351","DOI":"10.1111\/cge.12351"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Baba LA, Ailal F, El Hafidi N, Hubeau M, Jabot-Hanin F, Benajiba N, et al. Chronic granulomatous disease in Morocco: genetic, immunological, and clinical features of 12 patients from 10 kindreds. J Clin Immunol. 2014;34(4):452-458. DOI: 10.1007\/s10875-014-9997-3","DOI":"10.1007\/s10875-014-9997-3"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Shalinda Jude Arjuna Fernando, Noorul Mifra Faiz, Shiroma Mangaika Handunnett, Aruna Dharshan De Silva, Wasala Mudiyanselage Dhanushka Kumari Dasanayake, Geethani Devika Wickramasinghe, et al. Preliminary study on chronic granulomatous disease in Sri Lanka. Allergy Asthma Clin Immunol. 2018;14:37. DOI: 10.1186\/s13223-018-0264-7","DOI":"10.1186\/s13223-018-0264-7"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Martel C, Mollin M, Beaumel S, Brion JP, Coutton C, Satre V, et al. Clinical, functional and genetic analysis of twenty-four patients with chronic granulomatous disease - identification of eight novel mutations in CYBB and NCF2 genes. J Clin Immunol. 2012;32(5):942-958. DOI: 10.1007\/s10875-012-9698-8","DOI":"10.1007\/s10875-012-9698-8"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Bakri FG, Martel C, Khuri-Bulos N, Mahafzah A, El-Khateeb MS, Al-Wahadneh AM, et al. First report of clinical, functional, and molecular investigation of chronic granulomatous disease in nine Jordanian families. J Clin Immunol. 2009;29(2):215-230. DOI: 10.1007\/s10875-008-9243-y","DOI":"10.1007\/s10875-008-9243-y"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Teimourian S, Rezvani Z, Badalzadeh M, Kannengiesser C, Mansouri D, Movahedi M, et al. Molecular diagnosis of X-linked chronic granulomatous disease in Iran. Int J Hematol. 2008;87(4):398-404. DOI: 10.1007\/s12185-008-0060-0","DOI":"10.1007\/s12185-008-0060-0"},{"key":"ref71","unstructured":"World Health Organization. Global tuberculosis report 2020. Suiza: World Health Organization; 2020."},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Robles-Marhuenda A, Alvarez-Troncoso J, Rodriguez-Pena R, Busca-Arenzana C, Lopez-Granados E, Arnalich-Fernandez F. Chronic granulomatous disease: Single-center Spanish experience. Clin Immunol. 2019;211:108323. DOI: 10.1016\/j.clim.2019.108323","DOI":"10.1016\/j.clim.2019.108323"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Campos LC, di Colo G, Dattani V, Braggins H, Kumararatne D, Williams AP, et al. Long-term outcomes for adults with chronic granulomatous disease in the United Kingdom. J Allergy Clin Immunol. 2021;147(3):1104-1107. DOI: 10.1016\/j.jaci.2020.08.034","DOI":"10.1016\/j.jaci.2020.08.034"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Beghin A, Comini M, Soresina A, Imberti L, Zucchi M, Plebani A, et al. Chronic granulomatous disease in children: a single center experience. Clin Immunol. 2018;188:12-19. DOI: 10.1016\/j.clim.2017.11.016","DOI":"10.1016\/j.clim.2017.11.016"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Raptaki M, Varela I, Spanou K, Tzanoudaki M, Tantou S, Liatsis M, et al. Chronic granulomatous disease: a 25-year patient registry based on a multistep diagnostic procedure, from the referral center for primary immunodeficiencies in Greece. J Clin Immunol. 2013;33(8):1302-1309. DOI: 10.1007\/s10875-013-9940-z","DOI":"10.1007\/s10875-013-9940-z"},{"key":"ref76","unstructured":"Turul-Ozg\u00fcr T, T\u00fcrkkani-Asal G, Tezcan I, K\u00f6ker MY, Metin A, Yel L, et al. Clinical features of chronic granulomatous disease: a series of 26 patients from a single center. Turk J Pediatr. 2010;52(6):576-581."},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Wolach B, Gavrieli R, de Boer M, Gottesman G, Ben-Ari J, Rottem M, et al. Chronic granulomatous disease in Israel: clinical, functional and molecular studies of 38 patients. Clin Immunol. 2008;129(1):103-114. DOI: 10.1016\/j.clim.2008.06.012","DOI":"10.1016\/j.clim.2008.06.012"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Martire B, Rondelli R, Soresina A, Pignata C, Broccoletti T, Finocchi A, et al. Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study. Clin Immunol. 2008;126(2):155-164. DOI: 10.1016\/j.clim.2007.09.008","DOI":"10.1016\/j.clim.2007.09.008"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Carnide EG, Jacob CA, Castro AM, Pastorino AC. Clinical and laboratory aspects of chronic granulomatous disease in description of eighteen patients. Pediatr Allergy Immunol. 2005;16(1):5-9. DOI: 10.1111\/j.1399-3038.2005.00225.x","DOI":"10.1111\/j.1399-3038.2005.00225.x"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Barese C, Copelli S, Zandomeni R, Oleastro M, Zelazko M, Rivas EM. X-linked chronic granulomatous disease: first report of mutations in patients of Argentina. J Pediatr Hematol Oncol. 2004;26(10):656-660. DOI: 10.1097\/01.mph.0000139455.29962.be","DOI":"10.1097\/01.mph.0000139455.29962.be"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Oh H-B, Park JS, Lee W, Yoo SJ, Yang JH, Oh S-Y. Molecular analysis of X-linked chronic granulomatous disease in five unrelated Korean patients. J Korean Med Sci. 2004;19(2):218-222. DOI: 10.3346\/jkms.2004.19.2.218","DOI":"10.3346\/jkms.2004.19.2.218"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Liese J, Kloos S, Jendrossek V, Petropoulou T, Wintergerst U, Notheis G, et al. Long-term follow-up and outcome of 39 patients with chronic granulomatous disease. J Pediatr. 2000;137(5):687-693. DOI: 10.1067\/mpd.2000.109112","DOI":"10.1067\/mpd.2000.109112"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Hasui M. Chronic granulomatous disease in Japan: Incidence and natural history. The Study Group of Phagocyte Disorders of Japan. Pediatr Int. 1999;41(5):589-593. DOI: 10.1046\/j.1442-200x.1999.01129.x","DOI":"10.1046\/j.1442-200x.1999.01129.x"}],"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/859\/1442","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/859\/1493","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/859\/1453","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/859\/1442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:14:56Z","timestamp":1744215296000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,22]]},"references-count":84,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,8,22]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v658i2.859","relation":{},"ISSN":["2448-9190","0002-5151"],"issn-type":[{"type":"electronic","value":"2448-9190"},{"type":"print","value":"0002-5151"}],"subject":[],"published":{"date-parts":[[2021,8,22]]}}}